Wire · market
ESMO: Incyte feels 'neck and neck' with RevMed in KRAS G12D race
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Incyte presented promising phase 1 results for its KRAS G12D inhibitor INCB161734 in pancreatic and colorectal cancers at ESMO 2026, showing efficacy comparable to Revolution Medicines' zoldonrasib. Both companies are advancing late-stage trials in first-line metastatic pancreatic cancer, signalling a highly competitive race in this newly focused cancer target.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You face a tight race in KRAS G12D pancreatic therapies with Incyte and Revolution Medicines neck and neck; action your clinical strategy now to catch the next wave of approval-driven demand. Investors and partners will target companies with phase 3 momentum and combinational data like INCB161734 offers.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics